$2.59T
Total marketcap
$167.51B
Total volume
BTC 50.07%     ETH 15.77%
Dominance

Celldex Therapeutics CLDX Stock

40.96 USD {{ price }} -2.499403% {{change_pct}}%
Exchange
NasdaqCM
Market Cap
2.69B USD
LOW - HIGH [24H]
40.89 - 42.4 USD
VOLUME [24H]
949K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.92 USD

Celldex Therapeutics Price Chart

Celldex Therapeutics CLDX Financial and Trading Overview

Celldex Therapeutics stock price 40.96 USD
Previous Close 37.6 USD
Open 37.36 USD
Bid 0 USD x 1400
Ask 0 USD x 1800
Day's Range 36.64 - 38.06 USD
52 Week Range 21.65 - 48.4 USD
Volume 339.36K USD
Avg. Volume 632.67K USD
Market Cap 1.74B USD
Beta (5Y Monthly) 2.127816
PE Ratio (TTM) N/A
EPS (TTM) -2.92 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 66.33 USD

CLDX Valuation Measures

Enterprise Value 1.47B USD
Trailing P/E N/A
Forward P/E -12.414141
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 553.0793
Price/Book (mrq) 5.753745
Enterprise Value/Revenue 465.861
Enterprise Value/EBITDA -12.991

Trading Information

Celldex Therapeutics Stock Price History

Beta (5Y Monthly) 2.127816
52-Week Change 58.51%
S&P500 52-Week Change 20.43%
52 Week High 48.4 USD
52 Week Low 21.65 USD
50-Day Moving Average 33.26 USD
200-Day Moving Average 36.7 USD

CLDX Share Statistics

Avg. Volume (3 month) 632.67K USD
Avg. Daily Volume (10-Days) 557.78K USD
Shares Outstanding 47.25M
Float 44.02M
Short Ratio 13.45
% Held by Insiders 0.30%
% Held by Institutions 105.54%
Shares Short 5.8M
Short % of Float 14.93%
Short % of Shares Outstanding 12.28%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:15

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -3675.36%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -19.33%
Return on Equity (ttm) -33.85%

Income Statement

Revenue (ttm) 3.15M USD
Revenue Per Share (ttm) 0.07 USD
Quarterly Revenue Growth (yoy) 455.70%
Gross Profit (ttm) -79901000 USD
EBITDA -112963000 USD
Net Income Avi to Common (ttm) -118636000 USD
Diluted EPS (ttm) -2.44
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 278.39M USD
Total Cash Per Share (mrq) 5.89 USD
Total Debt (mrq) 3.65M USD
Total Debt/Equity (mrq) 1.21 USD
Current Ratio (mrq) 19.029
Book Value Per Share (mrq) 6.408

Cash Flow Statement

Operating Cash Flow (ttm) -107767000 USD
Levered Free Cash Flow (ttm) -54598752 USD

Profile of Celldex Therapeutics

Country United States
State NJ
City Hampton
Address Perryville III Building
ZIP 08827
Phone 908 200 7500
Website https://www.celldex.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 148

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Q&A For Celldex Therapeutics Stock

What is a current CLDX stock price?

Celldex Therapeutics CLDX stock price today per share is 40.96 USD.

How to purchase Celldex Therapeutics stock?

You can buy CLDX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Celldex Therapeutics?

The stock symbol or ticker of Celldex Therapeutics is CLDX.

Which industry does the Celldex Therapeutics company belong to?

The Celldex Therapeutics industry is Biotechnology.

How many shares does Celldex Therapeutics have in circulation?

The max supply of Celldex Therapeutics shares is 65.7M.

What is Celldex Therapeutics Price to Earnings Ratio (PE Ratio)?

Celldex Therapeutics PE Ratio is now.

What was Celldex Therapeutics earnings per share over the trailing 12 months (TTM)?

Celldex Therapeutics EPS is -2.92 USD over the trailing 12 months.

Which sector does the Celldex Therapeutics company belong to?

The Celldex Therapeutics sector is Healthcare.

Celldex Therapeutics CLDX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
NASDAQ Capital Market Composite RCMP 116.84 USD
-0.68
116.47 USD 117.72 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD